PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCL2 (Chemokine (C-C motif) ligand 2)

icosapent ethyl

5ms

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia (clinicaltrials.gov)

P3, N=316, Completed, Mochida Pharmaceutical Company, Ltd. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Jul 2023 | Trial primary completion date: Dec 2023 --> Jul 2023

5 months ago

Trial completion • Trial completion date • Trial primary completion date

icosapent ethyl

6ms

Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation. (PubMed, J Am Heart Assoc)

These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.

6 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • ICAM1 (Intercellular adhesion molecule 1)

icosapent ethyl

6ms

The sphingosine-1-phosphate receptor 1 mediates the atheroprotective effect of eicosapentaenoic acid. (PubMed, Nat Metab)

Finally, we show that Vascepa, a prescription drug containing highly purified and stable EPA ethyl ester, exerts its cardiovascular protective effect through the 17,18-EEQ-S1PR1 pathway in male and female mice. Collectively, our findings indicate that the anti-inflammatory effect of 17,18-EEQ involves the activation of the S1PR1-Gq-Ca2+-eNOS axis in ECs, offering a potential therapeutic target against atherosclerosis.

6 months ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • NOS3 (Nitric oxide synthase 3) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)

icosapent ethyl

6ms

SALVAGE: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion (clinicaltrials.gov)

P2, N=110, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

6 months ago

New P2 trial

icosapent ethyl

9ms

IPE-PREVENTION: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk (clinicaltrials.gov)

P4, N=70, Completed, Canadian Medical and Surgical Knowledge Translation Research Group | Active, not recruiting --> Completed

9 months ago

Trial completion

CRP (C-reactive protein)

icosapent ethyl

9ms

ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov)

P4, N=200, Recruiting, University of Louisville | Not yet recruiting --> Recruiting

9 months ago

Enrollment open

icosapent ethyl

10ms

ARTCAP: Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (clinicaltrials.gov)

P4, N=200, Not yet recruiting, University of Louisville

10 months ago

New P4 trial

icosapent ethyl

12ms

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)

P1/2, N=1, Terminated, National Cancer Institute (NCI) | N=18 --> 1 | Trial completion date: Jun 2026 --> Dec 2023 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2023; Other - Poor accrual

12 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • EPHA2 (EPH receptor A2) • ABCA1 (ATP Binding Cassette Subfamily A Member 1)

PGR expression

dasatinib • icosapent ethyl

1year

BRAVE-EPA: Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (clinicaltrials.gov)

P2/3, N=131, Completed, VA Office of Research and Development | Active, not recruiting --> Completed

1 year ago

Trial completion

icosapent ethyl

1year

EMT2: EPA for Metastasis Trial 2 (clinicaltrials.gov)

P3, N=418, Active, not recruiting, Mark A Hull, PhD FRCP | Recruiting --> Active, not recruiting

1 year ago

Enrollment closed • Surgery

icosapent ethyl

2years

IMPACT OF ICOSAPENT ETHYL ON ALZHEIMERS DISEASE BIOMARKERS IN PRECLINICAL ADULTS: BRAIN AMYLOID AND VASCULAR EFFECTS OF EIOSCAPENTAEOIC ACID (BRAVE-EPA) STUDY DESIGN AND BASELINE CHARACTERISTICS. (CTAD 2022)

"US military Veterans are an important cohort to study in identifying mechanisms to reduce AD risk. These data support the feasibility of recruiting cognitively unimpaired Veterans into a randomized, placebo-controlled clinical trial assessing the impact of IPE on MRI, CSF, and cognitive AD biomarkers. Trial data collection is ongoing and will be completed in September 2023."

2 years ago

Preclinical

icosapent ethyl

over2years

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)

P1/2, N=18, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Jun 2026 | Trial primary completion date: Jun 2023 --> Jun 2026

over 2 years ago

Enrollment open • Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CASP3 (Caspase 3)

PGR expression

dasatinib • icosapent ethyl

almost3years

Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov)

P1/2, N=18, Not yet recruiting, National Cancer Institute (NCI)

almost 3 years ago

New P1/2 trial

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CASP3 (Caspase 3)

PGR expression

dasatinib • icosapent ethyl

3years

OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer (clinicaltrials.gov)

P2, N=0, Withdrawn, Massachusetts General Hospital | N=36 --> 0 | Trial completion date: Sep 2023 --> Nov 2021 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2021 --> Nov 2021

3 years ago

Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • IO biomarker

PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • FOXP3 (Forkhead Box P3)

icosapent ethyl

3years

Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases (clinicaltrials.gov)

P=N/A, N=250, Recruiting, University of Leeds | Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Sep 2021

3 years ago

Enrollment open • Trial initiation date • IO biomarker

PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCL2 (Chemokine (C-C motif) ligand 2)

icosapent ethyl

almost4years

Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases (clinicaltrials.gov)

P, N=250, Not yet recruiting, University of Leeds

almost 4 years ago

New trial • IO biomarker

icosapent ethyl